Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NRXP Stock 12 Month Forecast
Average Price Target
$32.50
▲(1377.27% Upside)
| Highest Price Target$40.00 | Average Price Target$32.50 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
BTIG
$25
Buy
1036.36%
Upside
Reiterated
12/08/25
H.C. Wainwright
$40
Buy
1718.18%
Upside
Reiterated
11/20/25
NRX Pharmaceuticals: Advancing Towards Revenue Generation and FDA Approval with Strategic DevelopmentsValuation and Risks. We value NRx Pharmaceuticals using a sum-of-the-parts (SOTP) and risk-adjusted discounted cash flow (DCF) methodology. We assign a probability of success of 60% to NRX-100 in suicidal depression, and of 60% to NRX-101 in bipolar depression with suicidality and/or akathisia. We include build in revenues from NRX-100 general use starting in 2026E that leads to a moderate present value. We apply a 12% discount rate and a 6x terminal EV/EBITDA multiple, with additional value attributed to HOPE based on projected EBITDA and potential spin-out.
D. Boral Capital
$31→$34
Buy
1445.45%
Upside
Reiterated
08/22/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
BTIG
$25
Buy
1036.36%
Upside
Reiterated
12/08/25
H.C. Wainwright
$40
Buy
1718.18%
Upside
Reiterated
11/20/25
NRX Pharmaceuticals: Advancing Towards Revenue Generation and FDA Approval with Strategic DevelopmentsValuation and Risks. We value NRx Pharmaceuticals using a sum-of-the-parts (SOTP) and risk-adjusted discounted cash flow (DCF) methodology. We assign a probability of success of 60% to NRX-100 in suicidal depression, and of 60% to NRX-101 in bipolar depression with suicidality and/or akathisia. We include build in revenues from NRX-100 general use starting in 2026E that leads to a moderate present value. We apply a 12% discount rate and a 6x terminal EV/EBITDA multiple, with additional value attributed to HOPE based on projected EBITDA and potential spin-out.
D. Boral Capital
$31→$34
Buy
1445.45%
Upside
Reiterated
08/22/25
Best Analysts Covering NRX Pharmaceuticals
1 Month
xxx
Success Rate
4/6 ratings generated profit
Average Return
+8.02%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +8.02% per trade.
3 Months
xxx
Success Rate
4/6 ratings generated profit
Average Return
+10.68%
reiterated a xxx
rating 6 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +10.68% per trade.
1 Year
Success Rate
2/6 ratings generated profit
Average Return
-6.82%
reiterated a buy rating 6 days ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -6.82% per trade.
2 Years
xxx
Success Rate
5/10 ratings generated profit
Average Return
-18.98%
reiterated a xxx
rating 8 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -18.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NRXP Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
6
8
6
7
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
8
6
7
Each month's total comprises the sum of three months' worth of ratings.
NRXP Financial Forecast
NRXP Stock Forecast FAQ
What is NRXP’s average 12-month price target, according to analysts?
Based on analyst ratings, NRX Pharmaceuticals’s 12-month average price target is 32.50.
What is NRXP’s upside potential, based on the analysts’ average price target?
NRX Pharmaceuticals has 1377.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NRXP a Buy, Sell or Hold?
NRX Pharmaceuticals has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is NRX Pharmaceuticals’s price target?
The average price target for NRX Pharmaceuticals is 32.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $40.00 ,the lowest forecast is $25.00. The average price target represents 1377.27% Increase from the current price of $2.2.
The highest analyst price target is $40.00 ,the lowest forecast is $25.00. The average price target represents 1377.27% Increase from the current price of $2.2.
What do analysts say about NRX Pharmaceuticals?
NRX Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of NRXP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.